These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 18439942)

  • 1. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas.
    Gejman R; Swearingen B; Hedley-Whyte ET
    Hum Pathol; 2008 May; 39(5):758-66. PubMed ID: 18439942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
    Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
    Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
    Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A classification tree approach for pituitary adenomas.
    Righi A; Agati P; Sisto A; Frank G; Faustini-Fustini M; Agati R; Mazzatenta D; Farnedi A; Menetti F; Marucci G; Foschini MP
    Hum Pathol; 2012 Oct; 43(10):1627-37. PubMed ID: 22446019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas].
    Miyagami M; Nakamura S
    No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
    Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
    Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.
    Losa M; Franzin A; Mangili F; Terreni MR; Barzaghi R; Veglia F; Mortini P; Giovanelli M
    Neurosurgery; 2000 Dec; 47(6):1313-8; discussion 1318-9. PubMed ID: 11126902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
    Saeger W; Lüdecke B; Lüdecke DK
    Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
    Matsuyama J
    Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD147 expression in pituitary adenomas and its significance for clinical outcome.
    Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G
    Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The abnormalities in the p53/p21WAF1 pathway have a significant role in the pathogenesis and progression of gastrointestinal stromal tumors.
    Chou YP; Lin JW; Wang CC; Chiu YC; Huang CC; Chuah SK; Tai MH; Yi LN; Lee CM; Changchien CS; Hu TH
    Oncol Rep; 2008 Jan; 19(1):49-56. PubMed ID: 18097575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of proliferation biomarkers and p53 expression in rectal mucosa and sporadic colonic adenomas: a prospective study.
    Freitas D; Goulão MH; Camacho E; Figueiredo P; Ministro P; Ferreira M; Portela F; Andrade P; Donato A; Martins MI
    Hepatogastroenterology; 2002; 49(47):1269-74. PubMed ID: 12239922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
    Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
    Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
    Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
    Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
    Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
    Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of p53 and Ki-67 expression in resected or biopsy specimens of bile duct carcinoma.
    Murakami M; Sasaki T; Kuwada Y; Yamasaki S; Kuwahara K; Chayama K
    Oncol Rep; 2003; 10(5):1091-6. PubMed ID: 12883663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
    Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S
    J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
    Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
    Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathobiology of pituitary adenomas and carcinomas.
    Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
    Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic markers of invasive pituitary adenomas involving the sphenoid sinus.
    Gandour-Edwards R; Kapadia SB; Janecka IP; Martinez AJ; Barnes L
    Mod Pathol; 1995 Feb; 8(2):160-4. PubMed ID: 7777477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.